Fosnetupitant chloride hydrochloride; palonosetron hydrochloride - Generic Drug Details

What are the generic drug sources for fosnetupitant chloride hydrochloride; palonosetron hydrochloride and what is the scope of freedom to operate?

Fosnetupitant chloride hydrochloride; palonosetron hydrochloride is the generic ingredient in one branded drug marketed by Helsinn Hlthcare and is included in one NDA. There are twelve patents protecting this compound. Additional information is available in the individual branded drug profile pages.

Fosnetupitant chloride hydrochloride; palonosetron hydrochloride has one hundred and eighty-four patent family members in fifty-three countries.

One supplier is listed for this compound.

Summary for fosnetupitant chloride hydrochloride; palonosetron hydrochloride

International Patents:	184
US Patents:	12
Tradenames:	1
Applicants:	1
NDAs:	1
Finished Product Suppliers / Packagers:	1
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for fosnetupitant chloride hydrochloride; palonosetron hydrochloride
DailyMed Link:	fosnetupitant chloride hydrochloride; palonosetron hydrochloride at DailyMed

DrugPatentWatch^® Estimated Loss of Exclusivity (LOE) Date for fosnetupitant chloride hydrochloride; palonosetron hydrochloride

Dosage:

POWDER;INTRAVENOUS

^*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.

Pharmacology for fosnetupitant chloride hydrochloride; palonosetron hydrochloride

Drug Class	Serotonin-3 Receptor Antagonist
Mechanism of Action	Serotonin 3 Receptor Antagonists

Anatomical Therapeutic Chemical (ATC) Classes for fosnetupitant chloride hydrochloride; palonosetron hydrochloride

A04AA	Serotonin (5HT3) antagonists
A04A	ANTIEMETICS AND ANTINAUSEANTS
A04	ANTIEMETICS AND ANTINAUSEANTS
A	Alimentary tract and metabolism

Paragraph IV (Patent) Challenges for FOSNETUPITANT CHLORIDE HYDROCHLORIDE; PALONOSETRON HYDROCHLORIDE

Tradename	Dosage	Ingredient	Strength	NDA	ANDAs Submitted	Submissiondate
AKYNZEO	Solution in SDV	fosnetupitant chloride hydrochloride; palonosetron hydrochloride	235 mg/0.25 mg per 20 mL	210493	1	2022-04-19

US Patents and Regulatory Information for fosnetupitant chloride hydrochloride; palonosetron hydrochloride

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Helsinn Hlthcare	AKYNZEO	fosnetupitant chloride hydrochloride; palonosetron hydrochloride	POWDER;INTRAVENOUS	210493-001	Apr 19, 2018		DISCN	Yes	No			Y	Y
Helsinn Hlthcare	AKYNZEO	fosnetupitant chloride hydrochloride; palonosetron hydrochloride	SOLUTION;INTRAVENOUS	210493-002	May 27, 2020		RX	Yes	Yes			Y	Y
Helsinn Hlthcare	AKYNZEO	fosnetupitant chloride hydrochloride; palonosetron hydrochloride	SOLUTION;INTRAVENOUS	210493-002	May 27, 2020		RX	Yes	Yes

International Patents for fosnetupitant chloride hydrochloride; palonosetron hydrochloride

Country	Patent Number	Title	Estimated Expiration
Colombia	2018011686	Formulaciones inyectables fisiológicamente balanceadas de fosnetupitant
Netherlands	301047
Canada	2850644

Supplementary Protection Certificates for fosnetupitant chloride hydrochloride; palonosetron hydrochloride

Patent Number	Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
2785706	132020000000094	Italy		PRODUCT NAME: FOSNETUPITANT O UN SUO SALE FARMACEUTICAMENTE ACCETTABILE, IN PARTICOLARE IL SUO SALE CLORURO CLORIDRATO(AKYNZEO); AUTHORISATION NUMBER(S) AND DATE(S): EU/1/15/1001/001-002, 20200316
2785706	20C1029	France		PRODUCT NAME: FOSNETUPITANT OU UN DE SES SELS PHARMACEUTIQUEMENT ACCEPTABLES, EN PARTICULIER LE SEL DE CHLORHYDRATE DE CHLORURE DE FOSNETUPITANT; REGISTRATION NO/DATE: EU/1/15/1001 20200318
2785706	SPC/GB20/037	United Kingdom		PRODUCT NAME: FOSNETUPITANT; REGISTERED: UK EU/1/15/1001 (NI) 20200318; UK PLGB 12333/0017-0001 20200318

Market Dynamics and Financial Trajectory for Fosnetupitant Chloride Hydrochloride and Palonosetron Hydrochloride

Last updated: February 16, 2026

---

What are the current market positions of fosnetupitant chloride hydrochloride and palonosetron hydrochloride?

Fosnetupitant chloride hydrochloride and palonosetron hydrochloride are used for preventing chemotherapy-induced nausea and vomiting (CINV). Palonosetron hydrochloride is established as a second-generation 5-HT3 receptor antagonist, while fosnetupitant is a next-generation NK1 receptor antagonist.

Palonosetron has been on the market since 2008, with sales driven by its efficacy and safety profile. Fosnetupitant was approved in Japan in 2018, primarily viewed as a combination therapy component for CINV. The market position of fosnetupitant is limited to regions where it has gained regulatory approval.

How do regulatory approvals and regional availability impact market potential?

Palonosetron boasts extensive approval across the US, Europe, and Asia, driven by Pfizer’s commercialization. It accounts for a significant share of the CINV prophylactic market, with global sales estimated at over $500 million (2022).

Fosnetupitant's approval is confined mainly to Japan within the NK1 antagonist category. Its market adoption depends on regulatory expansion to other regions, clinical data benefits over existing NK1 antagonists, and strategic partnering.

What are the key market drivers for these drugs?

• Cancer Treatment Growth: Rising global cancer incidence increases demand for antiemetics.
• Treatment Guidelines: Adoption of combination regimens including 5-HT3 antagonists and NK1 receptor antagonists, such as fosnetupitant, to improve CINV control.
• Enhanced Efficacy and Reduced Side Effects: Palonosetron’s longer half-life offers a dosing advantage.

What competitive dynamics influence future revenue?

Palonosetron faces competition from older agents like granisetron and newer 5-HT3 antagonists from Bayer and Sandoz. Its market share stabilizes on its proven efficacy.

Fosnetupitant competes with established NK1 antagonists like aprepitant and netupitant. Its limited regional presence constrains its global market share, but clinical advantages or cost benefits could propel growth if adopted outside Japan.

How do pricing and reimbursement policies impact revenue?

Palonosetron’s premium pricing is partially offset by broad reimbursement coverage in major markets, supporting stable revenues. Fosnetupitant, due to regional approval and patent protections, commands high pricing in Japan, with limited coverage elsewhere.

Reimbursement dynamics favor drugs with proven clinical benefits and cost-effectiveness. Variability in reimbursement policies affects market penetration, particularly for newly approved drugs.

What is the financial outlook for these drugs over the next five years?

• Palonosetron: Expected to maintain annual sales growth of 1-3%, reaching approximately $550-600 million by 2027. Market saturation and competition are factors that limit rapid growth.
• Fosnetupitant: Primarily confined to Japan, with sales estimated at $50-100 million in 2022. Its global expansion and regulatory approvals are prerequisites for substantial growth.

Potential catalysts include new clinical data, inclusion in international treatment guidelines, and strategic licensing deals for fosnetupitant outside Japan.

What future challenges could impact their trajectories?

• Patent expirations could reduce prices and margins.
• Competition from biosimilars and alternative therapies compromising market share.
• Regulatory hurdles and delayed approvals in other regions limit market expansion.
• Shifts in clinical practice protocols toward oral or alternative antiemetics.

---

Key Takeaways

• Palonosetron dominates the global CINV market with stable revenues; growth is moderate.
• Fosnetupitant has localized significance in Japan; expansion hinges on regulatory approvals.
• Market growth is driven by increasing cancer incidence and improved treatment regimens.
• Competitive pressures and reimbursement policies shape revenue trajectories.
• Strategic collaborations could expand fosnetupitant's reach, impacting future revenues.

---

FAQs

1. Will fosnetupitant gain broader international approval?
Potentially, contingent on clinical data demonstrating advantages over existing NK1 antagonists and successful submission to regulatory agencies outside Japan.

2. How does palonosetron compare to first-generation 5-HT3 antagonists?
Palonosetron has a longer half-life and higher receptor binding affinity, leading to superior efficacy and less frequent dosing.

3. What are the main price drivers for these drugs?
Reimbursement coverage, clinical efficacy, and competition influence pricing strategies. Patents help sustain premium pricing.

4. Are new antiemetics jeopardizing market share?
Emerging agents with improved tolerability or oral formulations could impact market dynamics, but current drugs maintain established roles.

5. What strategic moves could enhance fosnetupitant's market presence?
Obtaining approvals in additional regions, demonstrating cost-effectiveness, and forming licensing partnerships are key strategies.

---

References

1. Market research reports, 2022.
2. Pfizer corporate disclosures, 2022.
3. Regional regulatory agencies, 2022.
4. Industry analysis, 2022.
5. Clinical trial data, 2020-2022.